Barclays analyst Balaji Prasad raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $62 from $60 and keeps an Overweight rating on the shares. The firm increased estimates for the company ahead of the Q4 report.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.